摘要
目的观察艾迪注射液联合顺铂与氟尿嘧啶治疗晚期食管癌的临床疗效。方法将46例晚期食管癌患者随机分为观察组（24例）和对照组（22例）,观察组给予顺铂30 mg·m^-2,静脉注射,第1-3天,氟尿嘧啶500 mg·m^-2,静脉注射,第1-5天,28天为1个周期,连用2个周期,化疗同时给予艾迪注射液,50 mL加入5%葡萄糖注射液500 mL静脉滴注,每日1次,连用14天。对照组单纯化疗,方案同观察组。结果观察组和对照组近期疗效有效率分别为41.6%和40.9%,无显著性差异（P〉0.05）。观察组临床症状改善率和KPS评分提高率显著高于对照组（P〈0.05）,观察组II度以上白细胞和血小板减少的发生率显著低于对照组（P〈0.05）。结论艾迪注射液可以改善晚期食管癌患者的临床症状,减轻化疗不良反应,提高患者的生活质量,艾迪注射液联合PF方案化疗能取得更好的临床收益。
Objective To observe the therapeutic efficacy of Aidi injection combined with cisplation and 5-fluorouracil（PF regimen） chemotherapy in treatment of advanced esophageal cancer. Methods 46 cases of advanced esophageal cancer-were divided randomly into two groups. 24 patients of observation group were treated with Aidi injection（50 mL, d1-d14） combined with cisplation（DDP 30 mg·m^-2, d1-d3） and 5-fluorouracil（5-Fu 500 mg·m^-2, d1-d5）. A cycle last 28 days and they had continuous two cycles. 22 patients of control group only received PF Chemotherapy as observation group. The therapeutic efficacy of the two groups was evaluated after two cycles of treatment. Results The overall response rates of observation group and control group were respectively 41.6% and 40.9%, and there was no statistically significant difference（P〉0.05）. The symptoms control rate of observation group was higher than that of control group（P〈0.05）. The life quality of patients in observation group was superior to the patients in control group（P〈0.05）. Ⅱ-Ⅳ degree myelosuppression rate of observation group was lower than that of control group（P〈0.05）. Conclusion Aidi injection has the function of alleviating the symptoms and poisonous side-effect of chemotherapy medicine and improving life quality of patients with advanced esophageal cancer.
出处
《肿瘤药学》
CAS
2014年第1期62-65,共4页
Anti-Tumor Pharmacy
关键词
食管肿瘤
联合化疗
艾迪注射液
Esophageal Cancer
Chemotherapy
Aidi Injection
